Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical signed a non-exclusive agreement with Novo Nordisk to evaluate NPM-139, a semaglutide implant for chronic weight management. The deal allows Novo Nordisk to internally assess the implant using Vivani’s NanoPortal technology, signaling strong industry interest in the platform.
Key figures
- Drug Name
- NPM-139
- Phase Of Trial
- Phase 1
- Study start
- mid-2026
- Dosing frequency
- once- or twice-yearly
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.